What is the price-to-earnings ratio of Zynerba Pharmaceuticals?
The price-earnings ratio of Zynerba Pharmaceuticals is currently -1.61.
Zynerba Pharmaceuticals P/E 2024
Zynerba Pharmaceuticals P/E
-1.61
Ticker
ZYNE
ISIN
US98986X1090
WKN
A14XCV
As of Jun 18, 2024, Zynerba Pharmaceuticals's P/E ratio was -1.61, a 436.67% change from the -0.3 P/E ratio recorded in the previous year.
The Zynerba Pharmaceuticals P/E history
Zynerba Pharmaceuticals Aktienanalyse
What does Zynerba Pharmaceuticals do?
Zynerba Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe central nervous system disorders. The company was founded in 2007 and is headquartered in Devon, Pennsylvania, USA. The history of Zynerba Pharmaceuticals dates back to the discovery by Dr. Magid Abou-Gharbia, who led a team of scientists that developed a method for transporting cannabinoids through the blood-brain barrier. This groundbreaking discovery led to the formation of Zynerba Pharmaceuticals with the goal of developing novel cannabinoid-based therapies. Zynerba Pharmaceuticals' business model is based on the development of medical compounds derived from the cannabis plant. These compounds, known as cannabinoids, have the potential to treat a variety of different conditions related to the central nervous system. The company's strategy is to deliver these compounds in the form of transdermal patches to ensure optimal dosage and absorption by the body. Zynerba Pharmaceuticals is divided into different divisions that focus on specific conditions. The company's main division is the development of therapies for epilepsy based on the cannabinoid Zygel. Zygel is a synthetic cannabinoid administered as a transdermal patch and has high bioavailability. The patch is applied to the skin and delivers a precise dosage of Zygel to reduce seizures in patients with various forms of epilepsy. In addition, Zynerba Pharmaceuticals is working on therapies for neuropsychiatric disorders such as Fragile X syndrome, autism spectrum disorders, and schizophrenia. The company has a promising development pipeline and is currently involved in various clinical trials. The company has achieved many milestones and formed important partnerships to support its innovative research and development. In 2019, Zynerba Pharmaceuticals partnered with the Japanese company Daiichi Sankyo to expand its development pipeline. In summary, Zynerba Pharmaceuticals Inc offers a promising business model for the development of therapies for severe central nervous system disorders based on cannabinoids. The company has a promising development pipeline and has already formed important partnerships to support its research and development. Zynerba Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Zynerba Pharmaceuticals's P/E Ratio
The Price to Earnings (P/E) Ratio of Zynerba Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Zynerba Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Zynerba Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Zynerba Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Zynerba Pharmaceuticals Stock
How has the price-earnings ratio of Zynerba Pharmaceuticals changed compared to last year?
The price-to-earnings ratio of Zynerba Pharmaceuticals has increased by 436.67% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Zynerba Pharmaceuticals high compared to other companies?
Yes, the price-to-earnings ratio of Zynerba Pharmaceuticals is high compared to other companies.
How does an increase in the price-earnings ratio of Zynerba Pharmaceuticals affect the company?
An increase in the price-earnings ratio of Zynerba Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Zynerba Pharmaceuticals affect the company?
A decrease in the price-earnings ratio of Zynerba Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Zynerba Pharmaceuticals?
Some factors that influence the price-earnings ratio of Zynerba Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Zynerba Pharmaceuticals pay?
Over the past 12 months, Zynerba Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zynerba Pharmaceuticals is expected to pay a dividend of 0 USD.
What is the dividend yield of Zynerba Pharmaceuticals?
The current dividend yield of Zynerba Pharmaceuticals is .
When does Zynerba Pharmaceuticals pay dividends?
Zynerba Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals paid dividends every year for the past 0 years.
What is the dividend of Zynerba Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Zynerba Pharmaceuticals located?
Zynerba Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Zynerba Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Zynerba Pharmaceuticals from 6/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/18/2024.
When did Zynerba Pharmaceuticals pay the last dividend?
The last dividend was paid out on 6/18/2024.
What was the dividend of Zynerba Pharmaceuticals in the year 2023?
In the year 2023, Zynerba Pharmaceuticals distributed 0 USD as dividends.
In which currency does Zynerba Pharmaceuticals pay out the dividend?
The dividends of Zynerba Pharmaceuticals are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Zynerba Pharmaceuticals
Our stock analysis for Zynerba Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zynerba Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Zynerba Pharmaceuticals Revenue
- Zynerba Pharmaceuticals Net Income
- Zynerba Pharmaceuticals P/E
- Zynerba Pharmaceuticals P/S
- Zynerba Pharmaceuticals EBIT
- Zynerba Pharmaceuticals Dividend
- Zynerba Pharmaceuticals Stocks
- Zynerba Pharmaceuticals Market capitalization
- Zynerba Pharmaceuticals Debt
- Zynerba Pharmaceuticals Liabilities
- Zynerba Pharmaceuticals Equity
- Zynerba Pharmaceuticals AAQS
- Zynerba Pharmaceuticals Employees
- Zynerba Pharmaceuticals ROE
- Zynerba Pharmaceuticals ROA
- Zynerba Pharmaceuticals ROCE
